JPMorgan Chase & Co’s Design Therapeutics DSGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $61.8K | Sell |
18,325
-952
| -5% | -$3.21K | ﹤0.01% | 5013 |
|
|
2025
Q1 | $74.4K | Sell |
19,277
-69,938
| -78% | -$270K | ﹤0.01% | 4877 |
|
|
2024
Q4 | $550K | Buy |
89,215
+48,528
| +119% | +$299K | ﹤0.01% | 4103 |
|
|
2024
Q3 | $219K | Buy |
40,687
+26,503
| +187% | +$143K | ﹤0.01% | 4428 |
|
|
2024
Q2 | $47.5K | Sell |
14,184
-24,520
| -63% | -$82.1K | ﹤0.01% | 4920 |
|
|
2024
Q1 | $156K | Sell |
38,704
-2,556
| -6% | -$10.3K | ﹤0.01% | 4554 |
|
|
2023
Q4 | $109K | Sell |
41,260
-15,082
| -27% | -$40K | ﹤0.01% | 4731 |
|
|
2023
Q3 | $133K | Buy |
56,342
+4,359
| +8% | +$10.3K | ﹤0.01% | 4459 |
|
|
2023
Q2 | $327K | Buy |
51,983
+26,027
| +100% | +$164K | ﹤0.01% | 3993 |
|
|
2023
Q1 | $150K | Buy |
25,956
+6,156
| +31% | +$35.6K | ﹤0.01% | 4471 |
|
|
2022
Q4 | $203K | Sell |
19,800
-73,352
| -79% | -$752K | ﹤0.01% | 4203 |
|
|
2022
Q3 | $1.56M | Buy |
93,152
+74,863
| +409% | +$1.25M | ﹤0.01% | 3079 |
|
|
2022
Q2 | $256K | Sell |
18,289
-1,950
| -10% | -$27.3K | ﹤0.01% | 4204 |
|
|
2022
Q1 | $327K | Buy |
20,239
+4,504
| +29% | +$72.8K | ﹤0.01% | 4210 |
|
|
2021
Q4 | $337K | Buy |
15,735
+7,598
| +93% | +$163K | ﹤0.01% | 4270 |
|
|
2021
Q3 | $120K | Buy |
8,137
+142
| +2% | +$2.09K | ﹤0.01% | 4633 |
|
|
2021
Q2 | $159K | Buy |
+7,995
| New | +$159K | ﹤0.01% | 4587 |
|